111 (NASDAQ:YI) spotted trading -18.15% off 52-week high price. On the other end, the stock has been noted 228.53% away from the low price over the last 52-weeks. The stock changed -0.92% to recent value of $7.53. The stock transacted 476583 shares during most recent day however it has an average volume of 395.00K shares. The company has 86.76M of outstanding shares and 4.93M shares were floated in the market.

On May 08, 2020, 111 (NASDAQ:YI) a leading integrated online and offline healthcare platform in China, declared that it is launching a new diabetes patient management platform in cooperation with Lilly China.

The two companies will work together to build a comprehensive diabetes patient management platform that includes services such as disease management, disease education and patient support programs to enrich patients’ knowledge of chronic disease management and to better help diabetic patients to self-manage from home. The platform will seek to harness the power of internet hospital technologies, big data and artificial intelligence technologies to provide diabetic patients with a comprehensive digital health management solution.

111 has accumulated extensive experience in operations management in the area of chronic disease, especially in diabetes, laying a solid foundation for the development of the diabetes management platform. With the transformative power of technology, the platform will seek to provide patients with a one-stop solution for physician consultation + medication services, allowing patients to consult with qualified physicians online, and receive personalized healthcare management services, online refill service, and medication delivery services.

As the first multinational pharmaceutical company to join the platform, Lilly China will leverage its expertise in the field of diabetes management and will also offer a variety of patient management and support programs, including Lilly Connected Care Program and Patient Benefit Program, to eligible diabetes patients, with the aim of providing personalized disease education and health management services. In addition, with its deep experience in the diabetes field, Lilly China will help to develop a directory of disease education resources to help patients understand risk factors, signs and symptoms, and treatment options.

Its earnings per share (EPS) expected to touch remained -31.00% for this year. YI has a gross margin of 4.20% and an operating margin of -12.80% while its profit margin remained -12.60% for the last 12 months.

According to the most recent quarter its current ratio was 1.9 that represents company’s ability to meet its current financial obligations. The price moved ahead of 2.35% from the mean of 20 days, 10.54% from mean of 50 days SMA and performed 39.59% from mean of 200 days price. Company’s performance for the week was 4.15%, 5.17% for month and YTD performance remained 11.89%.